Clinical review of pulmonary embolism: Diagnosis, prognosis, and treatment

Medical Clinics of North America

Volumn 95, Issue 6, 2011, Pages 1203-1222

  Hunt, James M ^a   Bull, Todd M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Chronic thromboembolic disease; Pulmonary embolism; Venous thromboembolic disease

Indexed keywords

ALTEPLASE; ANTIVITAMIN K; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; STREPTOKINASE; UROKINASE;

ARTERIAL GAS; BLEEDING; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG HALF LIFE; ELECTROCARDIOGRAPHY; EMBOLECTOMY; HUMAN; LABORATORY TEST; LUNG EMBOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; THORAX RADIOGRAPHY; VENOUS THROMBOEMBOLISM;

ALGORITHMS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD GAS ANALYSIS; ELECTROCARDIOGRAPHY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GROWTH DIFFERENTIATION FACTOR 15; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYPONATREMIA; MAGNETIC RESONANCE IMAGING; MEDICAL HISTORY TAKING; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PULMONARY EMBOLISM; RISK FACTORS; THROMBOLYTIC THERAPY; TROPONIN; VENOUS THROMBOEMBOLISM; VENTILATION-PERFUSION RATIO; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 82455219233     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.08.003     Document Type: Review

References (79)

1. Heit J., Cohen A., Anderson F.J. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 2005, 106:267A.
2. Park B., Messina L., Dargon P., et al. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample. Chest 2009, 136:983-990.
3. Goldhaber S.Z. Epidemiology of pulmonary embolism. Semin Vasc Med 2001, 1:139-146.
4. Lee C.H., Cheng C.L., Lin L.J., et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J 2011, 75:1998-2004.
5. Gillum R.F. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 1987, 114:1262-1264.
6. Heit J.A., Silverstein M.D., Mohr D.N., et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999, 159:445-453.
7. Cohen A.T., Agnelli G., Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007, 98:756-764.
8. Heit J., Petterson T., Farmer S., et al. Trends in incidence of deep vein thrombosis and pulmonary embolism: a 35-year population-based study. Blood 2006, 108:430a.
9. Skaf E., Stein P.D., Beemath A., et al. Fatal pulmonary embolism and stroke. Am J Cardiol 2006, 97:1776-1777.
10. Silverstein M.D., Heit J.A., Mohr D.N., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998, 158:585-593.
11. Cervantes J., Rojas G. Virchow's legacy: deep vein thrombosis and pulmonary embolism. World J Surg 2005, 29(Suppl 1):S30-S34.
12. Dickson B.C. Venous thrombosis: on the history of Virchow's triad. Univ Toronto Med J 2004, 81:166-171.
13. Mateo J., Oliver A., Borrell M., et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997, 77:444-451.
14. Ridker P.M., Hennekens C.H., Lindpaintner K., et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995, 332:912-917.
15. Koster T., Rosendaal F.R., de R.H., et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993, 342:1503-1506.
16. Baglin T., Gray E., Greaves M., et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010, 149:209-220.
17. Spencer F.A., Emery C., Lessard D., et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006, 21:722-727.
18. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990, 263:2753-2759.
19. Becattini C., Vedovati M.C., Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007, 116:427-433.
20. Scherz N., Labarere J., Mean M., et al. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med 2010, 182:1178-1183.
21. La V.L., Ottani F., Favero L., et al. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. Heart 2004, 90:633-637.
22. Klok F.A., Mos I.C., Huisman M.V. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008, 178:425-430.
23. Lankeit M., Kempf T., Dellas C., et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 2008, 177:1018-1025.
24. Stein P.D., Goldhaber S.Z., Henry J.W., et al. Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest 1996, 109:78-81.
25. Righini M., Perrier A., De M.P., et al. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008, 6:1059-1071.
26. Dempfle C.E., Suvajac N., Elmas E., et al. Performance evaluation of a new rapid quantitative assay system for measurement of D-dimer in plasma and whole blood: PATHFAST D-dimer. Thromb Res 2007, 120:591-596.
27. van Belle A., Buller H.R., Huisman M.V., et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006, 295:172-179.
28. Kucher N., Printzen G., Goldhaber S.Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003, 107:2545-2547.
29. Coutance G., Le P.O., Lo T., et al. Prognostic value of brain natriuretic peptide in acute pulmonary embolism. Crit Care 2008, 12:R109.
30. Perrier A., Roy P.M., Sanchez O., et al. Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med 2005, 352:1760-1768.
31. Righini M., Le G.G., Aujesky D., et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet 2008, 371:1343-1352.
32. Turkstra F., Kuijer P.M., van Beek E.J., et al. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med 1997, 126:775-781.
33. Musset D., Parent F., Meyer G., et al. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet 2002, 360:1914-1920.
34. Johnson S.A., Stevens S.M., Woller S.C., et al. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA 2010, 303:438-445.
35. Kucher N., Rossi E., De R.M., et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005, 165:1777-1781.
36. Kasper W., Konstantinides S., Geibel A., et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997, 77:346-349.
37. Kreit J.W. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004, 125:1539-1545.
38. Hall W.B., Truitt S.G., Scheunemann L.P., et al. The prevalence of clinically relevant incidental findings on chest computed tomographic angiograms ordered to diagnose pulmonary embolism. Arch Intern Med 2009, 169:1961-1965.
39. Van Strijen M.J., De M.W., Kieft G.J., et al. Accuracy of single-detector spiral CT in the diagnosis of pulmonary embolism: a prospective multicenter cohort study of consecutive patients with abnormal perfusion scintigraphy. J Thromb Haemost 2005, 3:17-25.
40. Perrier A., Howarth N., Didier D., et al. Performance of helical computed tomography in unselected outpatients with suspected pulmonary embolism. Ann Intern Med 2001, 135:88-97.
41. Stein P.D., Fowler S.E., Goodman L.R., et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006, 354:2317-2327.
42. Blachere H., Latrabe V., Montaudon M., et al. Pulmonary embolism revealed on helical CT angiography: comparison with ventilation-perfusion radionuclide lung scanning. AJR Am J Roentgenol 2000, 174:1041-1047.
43. Stein P.D., Chenevert T.L., Fowler S.E., et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 2010, 152:434-443.
44. Wells P.S., Ginsberg J.S., Anderson D.R., et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998, 129:997-1005.
45. Wells P.S., Anderson D.R., Rodger M., et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000, 83:416-420.
46. Wicki J., Perrier A., Perneger T.V., et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000, 84:548-552.
47. Aujesky D., Obrosky D.S., Stone R.A., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005, 172:1041-1046.
48. Chan C.M., Woods C., Shorr A.F. The validation and reproducibility of the pulmonary embolism severity index. J Thromb Haemost 2010, 8:1509-1514.
49. Jimenez D., Yusen R.D., Otero R., et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest 2007, 132:24-30.
50. Donze J., Le G.G., Fine M.J., et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008, 100:943-948.
51. Jimenez D., Aujesky D., Moores L., et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010, 170:1383-1389.
52. Hariharan P., Takayesu J.K., Kabrhel C. Association between the Pulmonary Embolism Severity Index (PESI) and short-term clinical deterioration. Thromb Haemost 2011, 105:706-711.
53. Nurmohamed M.T., Rosendaal F.R., Buller H.R., et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992, 340:152-156.
54. Quinlan D.J., McQuillan A., Eikelboom J.W. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004, 140:175-183.
55. Simonneau G., Sors H., Charbonnier B., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997, 337:663-669.
56. Erkens P.M., Gandara E., Wells P., et al. Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost 2010, 8:2412-2417.
57. Kovacs M.J., Hawel J.D., Rekman J.F., et al. Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost 2010, 8:2406-2411.
58. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-1702.
59. Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
60. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
61. Ezekowitz M.D., Reilly P.A., Nehmiz G., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, 100:1419-1426.
62. Jerjes-Sanchez C., Ramirez-Rivera A., de Lourdes G.M., et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995, 2:227-229.
63. Kasper W., Konstantinides S., Geibel A., et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997, 30:1165-1171.
64. Konstantinides S., Geibel A., Heusel G., et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002, 347:1143-1150.
65. Clarke D.B., Abrams L.D. Pulmonary embolectomy: a 25 year experience. J Thorac Cardiovasc Surg 1986, 92:442-445.
66. Dauphine C., Omari B. Pulmonary embolectomy for acute massive pulmonary embolism. Ann Thorac Surg 2005, 79:1240-1244.
67. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998, 338:409-415.
68. PREPIC Study Group Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005, 112:416-422.
69. Van Ha T.G., Chien A.S., Funaki B.S., et al. Use of retrievable compared to permanent inferior vena cava filters: a single-institution experience. Cardiovasc Intervent Radiol 2008, 31:308-315.
70. Given M.F., McDonald B.C., Brookfield P., et al. Retrievable Gunther Tulip inferior vena cava filter: experience in 317 patients. J Med Imaging Radiat Oncol 2008, 52:452-457.
71. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:454S-545S.
72. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:401S-428S.
73. Lee A.Y., Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003, 107:I17-I21.
74. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
75. Pengo V., Lensing A.W., Prins M.H., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350:2257-2264.
76. Riedel M., Stanek V., Widimsky J., et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982, 81:151-158.
77. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
78. Jais X., D'Armini A.M., Jansa P., et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52:2127-2134.
79. Suntharalingam J., Treacy C.M., Doughty N.J., et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008, 134:229-236.